Shlok The team at Ath and Athe are extremely excited about the data but you seen somewhat negative…? David has mentioned many times that Pharmas are in daily contact..and that they are off ASAP to the FDA. Prof C would not have presented if he thought the data had no merit.. Anyway thanks for your opinion
“We are excited to present these new data from our double-blind Phase 2 trial, reinforcing thepotential of ATH434 to significantly modify disease progression in MSA. The clinical results fromthis study are important given the lack of available treatments to address the underlyingpathology in MSA,” said, David Stamler, M.D., Chief Executive Officer of Alterity. “Importantly,we saw clinically meaningful efficacy on multiple measures including the UMSARS1 I activities ofdaily living scale, the clinical global impression of severity, the orthostatic hypotension symptomassessment, and activity levels from wearable sensors. In addition, new analyses of neuroimagingdata show target engagement of ATH434 on iron levels in MSA affected regions of the brain. Welook forward to engaging with the U.S. Food and Drug Administration and other regulatoryauthorities as we seek to advance the development of this potentially disease modifying therapyfor individuals living with MSA.”
ATH Price at posting:
0.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)